Immunovant, Inc. (IMVT)

Immunovant Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-413.84	-259.34	-210.96	-156.73	-107.43
Depreciation & Amortization	0.38	0.23	0.19	0.13	0.07
Stock-Based Compensation	49.49	41.12	32.3	34.24	18.82
Other Operating Activities	0.13	1.13	1.13	1.11	0.65
Change in Accounts Receivable	3.23	-4.58	11.76	-11.63	-0.6
Change in Accounts Payable	10.68	5.78	-17.12	16.25	1.25
Change in Income Taxes	-0.26	0.02	0.46	-0.09	-0.51
Change in Other Net Operating Assets	-25.69	1.41	-5.95	10.61	4.42
Operating Cash Flow	-375.87	-214.23	-188.19	-106.11	-83.33
Capital Expenditures	-0.76	-0.36	-0.2	-0.25	-0.21
Investing Cash Flow	-0.76	-0.36	-0.2	-0.25	-0.21
Short-Term Debt Repaid	-	-	-	-	-3.19
Total Debt Repaid	-	-	-	-	-3.19
Net Debt Issued (Repaid)	-	-	-	-	-3.19
Issuance of Common Stock	454.81	478.44	71.16	200.13	387.54
Other Financing Activities	-0.32	-6.01	-0.27	-	-1.24
Financing Cash Flow	454.49	472.43	70.89	200.13	383.11
Foreign Exchange Rate Adjustments	0.75	0.99	0.22	-0.09	-
Net Cash Flow	78.61	258.83	-117.29	93.67	299.58
Free Cash Flow	-376.63	-214.59	-188.39	-106.37	-83.54
Free Cash Flow Per Share	-2.48	-1.55	-1.53	-0.97	-0.95
Cash Income Tax Paid	1.2	0.51	-	-	0.17
Levered Free Cash Flow	-227.82	-124.15	-107.82	-47.88	-43.79
Unlevered Free Cash Flow	-227.82	-124.15	-107.82	-47.88	-43.79
Change in Net Working Capital	3.08	-3.74	9.94	-15.53	-5.11

Updated May 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q